Choroideremia Pipeline Analysis
Posted By sthakur Posted On

Choroideremia Treatment Algorithm, Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, and Pipeline Analysis

Choroideremia Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Choroideremia Market. 

The assessment part of the report embraces in-depth Choroideremia commercial assessment and clinical assessment of the Choroideremia pipeline products from the pre-clinical developmental phase to the marketed phase. 

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Choroideremia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Choroideremia Market Size is expected to increase during the forecast period owing to the prevalence of Choroideremia, along with the expected launch of emerging therapies such as Spark Therapeutics’ SPK-7001, Biogen‘s BIIB111 (AAV2-REP1), and 4D Molecular Therapeutics’ 4D-110. The pipeline for Choroideremia brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.

Some of the key companies in the Choroideremia Market include:

  • Biogen
  • Spark Therapeutics
  • 4D Molecular Therapeutics (4DMT)

And many others.

Choroideremia Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Choroideremia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Choroideremia treatment.
  • Choroideremia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Choroideremia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Choroideremia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.   

Choroideremia Therapies covered in the report include:

  • Spark Therapeutics is developing SPK-7001 (AAV2-hCHM), which is also known as AAV2 hCHM, and currently, it is in phase I/II stage of development for the Treatment of Choroideremia. SPK-7001 is a novel bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant that was developed using Spark’s proprietary technology platform for selecting, designing, manufacturing, and formulating highly optimized gene therapies.
  • BIIB111 (AAV2-REP1) is a gene therapy that was being developed by Nightstar Therapeutics (now acquired by Biogen), and currently, the phase III stage of development for the treatment of Choroideremia was completed in December 2020.
  • 4D Molecular Therapeutics (4DMT) is developing 4D-110, gene therapy for the treatment of Choroideremia (CHM). In November 2018, the US Food and Drug Administration (FDA) has granted orphan drug designation to 4D-110 for the treatment of choroideremia.

The launch of these emerging therapies is expected to significantly impact the treatment scenario of Choroideremia in the coming years, 2021–2030.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Choroideremia.    
  • In the coming years, the Choroideremia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics are working to assess challenges and seek opportunities that could influence Choroideremia Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Choroideremia treatment market. Several potential therapies for Choroideremia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Choroideremia market size in the coming years.  
  • Our in-depth analysis of the Choroideremia pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

 

Table of Content

  1. Report Introduction
  2. Choroideremia 
  3. Choroideremia Current Treatment Patterns
  4. Choroideremia – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Choroideremia Late Stage Products (Phase-III)
  7. Choroideremia Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Choroideremia Discontinued Products
  13. Choroideremia Product Profiles
  14. Choroideremia Key Companies
  15. Choroideremia Key Products
  16. Dormant and Discontinued Products
  17. Choroideremia Unmet Needs
  18. Choroideremia Future Perspectives
  19. Choroideremia Analyst Review  
  20. Appendix
  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Latest Reports By DelveInsight:

Choroideremia Market Insight

DelveInsight’s “Choroideremia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Choroideremia market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Choroideremia Epidemiology Forecast

DelveInsight’s Choroideremia Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Choroideremia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Lymphatic Malformations Market

DelveInsight’s “Lymphatic Malformations Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lymphatic Malformations market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Acute Pyelonephritis Market

DelveInsight’s “Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Latest HealthCare Blogs By DelveInsight:

 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Info:
Shruti Thakur
DelveInsight Business Research
Email: [email protected]
Phone No: +91-9650213330
Website: https://www.delveinsight.com/
Connect With Us at: LinkedIn | Facebook | Twitter
Healthcare Blog
Get FREE sample copy at: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Comments (0)

Leave a Reply

Your email address will not be published.